Literature DB >> 21550136

Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.

Megan N Landis1, Carrie L Davis, Gary A Bellus, Stephen E Wolverton.   

Abstract

Muir-Torre syndrome (MTS) is an autosomal dominant genodermatosis caused by mutations in the DNA mismatch repair genes MLH1 and MSH2. This case describes a patient with an extensive family history of colon cancer who experienced the onset of multiple sebaceous adenomas and carcinomas after undergoing kidney transplantation and receiving immunosuppressive therapy. The finding of deficient MSH2 expression in the immunohistochemical analysis of a sebaceous carcinoma prompted genetic testing for a systemic mutation in the mismatch repair gene. A systemic mutation of the MSH2 gene was detected and, despite the absence of a visceral malignancy, the diagnosis of MTS was made. Immunosuppression has previously been thought to play a possible role in unmasking a latent MTS phenotype in transplant recipients, but systemic mutations have not previously been analyzed. The relationship between immunosuppression and sebaceous tumors with the possibility of unmasking a MTS phenotype in transplant recipients is discussed.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550136     DOI: 10.1016/j.jaad.2010.08.003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?

Authors:  Alessandro Vaisfeld; Martina Calicchia; Maria Grazia Pomponi; Emanuela Lucci-Cordisco; Luca Reggiani-Bonetti; Maurizio Genuardi
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

Review 2.  More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies.

Authors:  Zhu Shen; Jodi D Hoffman; Fei Hao; Eric Pier
Journal:  Oncologist       Date:  2012-06-15

Review 3.  Diagnostic error: what Muir-Torre syndrome has taught us.

Authors:  Dmitri Wall; Caitriona Bridget Hackett; Vourneen Healy; Bart Ramsay
Journal:  BMJ Case Rep       Date:  2015-03-20

Review 4.  Sebaceous Carcinoma: A Review of the Scientific Literature.

Authors:  Thomas Knackstedt; Faramarz H Samie
Journal:  Curr Treat Options Oncol       Date:  2017-08

5.  Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.

Authors:  G Ponti; G Pellacani; C Ruini; A Percesepe; C Longo; V Desmond Mandel; F Crucianelli; G Gorelli; A Tomasi
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

6.  Case Report: A Frameshift Mutation in MSH2 Exon 2 in a Kidney Recipient With Muir-Torre Syndrome.

Authors:  Yifei Feng; Jianqing Feng; Jianrong Bao
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

7.  Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality.

Authors:  Simone Ribero; Eugenio Sportoletti Baduel; Matteo Brizio; Franco Picciotto; Emi Dika; Maria Teresa Fierro; Giuseppe Macripò; Pietro Quaglino
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

8.  Sebaceous adenoma in the setting of immunosuppression for kidney transplantation.

Authors:  Jacob Reinhart; William D James
Journal:  JAAD Case Rep       Date:  2019-08-30

9.  Maintenance Intravenous Immunoglobulin Treatment for Multiple Sclerosis Coexisting with Ehlers-Danlos Syndrome and Muir-Torre Syndrome: A Case Study.

Authors:  Srishti Gupta; Mohnish Suri; Cris S Constantinescu
Journal:  Neurol Ther       Date:  2020-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.